A MULTICENTER STUDY, IN PHASE II, RANDOMIZED, DOUBLE-BLINDED, IN PARALLEL GROUPS, CONTROLLED WITH PLACEBO AND WITH AN ACTIVE SUBSTANCE, TO ESTABLISH THE DOSE, ON THE SAFETY AND EFFICACY OF THE ORAL ANTAGONIST OF RECEPTORS FOR NEUROKININ-1, GW679769, WHEN ADMINISTERED AT 50 MG, 100 MG AND 150 MG DAIRY DOSES IN ORAL TABLETS IN COMBINATION WITH ONDANSETRON CHLORHYDRATE AND DEXAMETHASONE FOR THE PREVENTION OF NAUSEA AND VOMITING INDUCED BY CHEMOTHERAPY IN SUBJECTS WITH CANCER WHO RECEIVE A HIGHLY EMETOGENIC CHEMOTHERAPY BASED ON CISPLATIN